SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J. --(BUSINESS WIRE)--Jun. 22, 2026-- Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan”), a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, today
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J. --(BUSINESS WIRE)--Jun. 17, 2026-- Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan”), a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, today
Patients treated with tonlamarsen experienced statistically significant reductions in plasma angiotensinogen levels and clinically meaningful changes in systolic blood pressure Results support initiation of Phase 2b clinical trial of tonlamarsen in patients with acute severe hypertension SOUTH SAN
New Phase 2 data on tonlamarsen in patients with uncontrolled hypertension to be presented in late-breaking session on Saturday, March 28 Prolaio to present LINK-HF2 research highlighting the role of continuous monitoring and novel biomarkers in advancing cardiovascular therapeutics and care
Andy Pasternak appointed chief strategy officer, bringing extensive leadership in biopharmaceutical business development and company growth Clinical data readouts expected in 2026 across all three late-stage programs, marking a significant step forward in addressing unmet cardiovascular needs in
